Medical Prognosis Institute A/S
Venlighedsvej 1
2970 Hoersholm,
Denmark
CVR: 28106351
www.medical-prognosis.com

Company Announcement – No. 48

MPI and Mundipharma EDO GmbH enters agreement of DRP™ for their anti cancer lead compound EDO-S101 in clinical trials

Hoersholm; December 7, 2015 – Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI and Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP™ biomarker for Mundipharma EDO's lead compound EDO-S101 for the treatment of cancer.
EDO-S101 is a first in class fusion molecule that combines two drugs' mechanism of action in the cancer cell in order to increase the effect of treatment.
MPI's specific DRP™ multiple biomarker for EDO-S101 is to identify those patients who have the highest likelihood of response to the combination of bendamustine and vorinostat. Thereby the response rate will increase and time and resources spent will decrease.

"We are excited at the prospect of our partner Mundipharma EDO moving into Phase I with a DRP™ biomarker developed by MPI A/S," **says adjunct professor Peter Buhl Jensen, M.D., Ph.d., CEO at MPI**. "This is precisely where MPI's DRP™ makes a difference, due to the fact that our technology can be used for all cancer diseases and for most anti cancer drugs on the market or under development," adds **adjunct professor Peter Buhl Jensen, M.D., Ph.d., CEO at MPI**.

Mundipharma EDO CEO Dr. Thomas Mehrling says *"We look forward to seeing a validation of MPI's DRP biomarker in our clinical trials".*

About the Anti Cancer drug candidate EDO-S101
EDO-S101 is a first in class fusion molecule that combines the DNA damaging effect of bendamustine with the pan-histone deacetylase inhibitor (HDACi), vorinostat, with the aim of increasing the efficacy of the alkylator through the HDACi-mediated chromatin relaxation.

About MPI's multiple biomarker called Drug Response Predictor - DRP™
MPI's lead product, the DRP™ diagnostic platform, is a tool to develop tumor-derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP™ has been tested in 32 trials, where 26 trials showed that drug-specific DRP™ Biomarkers could predict which patients had a positive effect of the treatment. The DRP™ platform has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP™ method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anticancer drug. Further to and in addition to this, individual patients' gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of those patients who have a high likelihood of response to the drug. The DRP™ platform can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US.

About MPI
Medical Prognosis Institute advances personalized medicine by partnering with cancer drug developers to apply its DRP™ diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics.

About Mundipharma EDO GmbH
Mundipharma EDO GmbH (Early Development in Oncology) is developing early stage assets in oncology for the Mundipharma

Network of independent associated companies. EDO is committed to increasing the treatment options available for cancer patients and improving their quality of life through the early development of small molecules and biologics

For further information, please contact

MPI
Peter Buhl Jensen, CEO
e-mail: pbj@medical-prognosis.com
Phone: +45 21 60 89 22

Mundipharma EDO GmbH
Dr. Thomas Mehrling M.D., Ph.D., Managing Director
thomas.mehrling@mundipharma-edo.com
Phone: +41 798 701948

Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark